-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC

Benzinga·02/24/2026 12:19:28
Listen to the news
  • In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions
  • Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions
  • Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs
  • Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant patients in Q3 2026